Recently, several small molecular inhibitors have been developed that target specifically the Y397 autophosphorylation of FAK, such as TAE226, a compound that shows effective inhibition of angiogenesis, and tumor growth when treated in combination with imatinib [31, 32]. Here, PTK2 is linked to neoplasm.